Human immune cells' behavior and survival under bioenergetically restricted conditions in an in vitro fracture hematoma model

Cellular and Molecular Immunology

Volumn 10, Issue 2, 2013, Pages 151-158

  Hoff, Paula ^a,b   Maschmeyer, Patrick ^a,b   Gaber, Timo ^a,b,c   Schütze, Tabea ^a,b   Raue, Tobias ^a,b   Schmidt Bleek, Katharina ^c,d   Dziurla, René ^a,b   Schellmann, Saskia ^a,b   Lohanatha, Ferenz Leonard ^a,b   Röhner, Eric ^a   Ode, Andrea ^c,d   Burmester, Gerd Rüdiger ^a,b   Duda, Georg N ^c,d   Perka, Carsten ^a,c   Buttgereit, Frank ^a,b,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^c Berlin Brandenburg Center for Regenerative Therapies   (Germany)

^d Julius Wolff Institut   (Germany)

Author keywords

apoptosis; fracture hematoma model; hypoxia; immune cells; inflammation

Indexed keywords

ANGIOGENIC FACTOR; GAMMA INTERFERON; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BIOENERGY; BONE MARROW CELL; CELL FUNCTION; CELL HYPOXIA; CELL POPULATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MODEL; FEMALE; FRACTURE HEMATOMA; HEMATOMA; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE;

AGED; ARTHROPLASTY, REPLACEMENT, HIP; CELL SURVIVAL; CELLS, CULTURED; CHEMOKINE CCL2; ENERGY METABOLISM; FEMALE; FEMUR; FRACTURES, BONE; HEMATOMA; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84874637984     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2012.56     Document Type: Article

References (33)

1. Mercier FE, Ragu C, Scadden DT. The bone marrow at the crossroads of blood and immunity. Nat Rev Immunol 2012; 12: 49-60.
2. Teti A. Bone development: overview of bone cells and signaling. Curr Osteoporos Rep 2011; 9: 264-273.
3. McKibbin B. The biology of fracture healing in long bones. J Bone Joint Surg Br 1978; 60-B: 150-162.
4. Remedios A. Bone and bone healing. Vet Clin North Am Small Anim Pract 1999; 29: 1029-1044.
5. Naik AA, Xie C, Zuscik MJ, Kingsley P, Schwarz EM, Awad H et al. Reduced COX-2 expression in aged mice is associated with impaired fracture healing. J Bone Miner Res 2009; 24: 251-264.
6. Gerstenfeld LC, Thiede M, Seibert K, Mielke C, Phippard D, Svagr B et al. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J Orthop Res 2003; 21: 670-675.
7. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O'Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002; 109: 1405-1415.
8. Kolar P, Schmidt-Bleek K, Schell H, Gaber T, Toben D, Schmidmaier G et al. The early fracture hematoma and its potential role in fracture healing. Tissue Eng Part B Rev 2010; 16: 427-434.
9. Schaffer M, Barbul A. Lymphocyte function in wound healing and following injury. Br J Surg 1998; 85: 444-460.
10. Simpson DM, Ross R. The neutrophilic leukocyte in wound repair a study with antineutrophil serum. J Clin Invest 1972; 51: 2009-2023.
11. Park JE, Barbul A. Understanding the role of immune regulation in wound healing. Am J Surg 2004; 187: 11S-16S.
12. Efron JE, Frankel HL, Lazarou SA, Wasserkrug HL, Barbul A. Wound healing and T-lymphocytes. J Surg Res 1990; 48: 460-463.
13. Toben D, Schroeder I, El Khassawna T, Mehta M, Hoffmann JE, Frisch JT et al. Fracture healing is accelerated in the absence of the adaptive immune system. J Bone Miner Res 2011; 26: 113-124.
14. Grundnes O, Reikeras O. The importance of the hematoma for fracture healing in rats. Acta Orthop Scand 1993; 64: 340-342.
15. Andrew JG, Andrew SM, Freemont AJ, Marsh DR. Inflammatory cells in normal human fracture healing. Acta Orthop Scand 1994; 65: 462-466.
16. Chung R, Cool JC, Scherer MA, Foster BK, Xian CJ. Roles of neutrophil-mediated inflammatory response in the bony repair of injured growth plate cartilage in young rats. J Leukoc Biol 2006; 80: 1272-1280.
17. Schmidt-Bleek K, Schell H, Kolar P, Pfaff M, Perka C, Buttgereit F et al. Cellular composition of the initial fracture hematoma compared to a muscle hematoma: a study in sheep. J Orthop Res 2009; 27: 1147-1151.
18. Dziurla R, Gaber T, Fangradt M, Hahne M, Tripmacher R, Kolar P et al. Effects of hypoxia and/or lack of glucose on cellular energy metabolism and cytokine production in stimulated human CD41 T lymphocytes. Immunol Lett 2010; 131: 97-105.
19. Tripmacher R, Gaber T, Dziurla R, Haupl T, Erekul K, Grutzkau A et al. Human CD41 T cells maintain specific functions even under conditions of extremely restricted ATP production. Eur J Immunol 2008; 38: 1631-1642.
20. Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003; 112: 645-657.
21. Kolar P, Gaber T, Perka C, Duda GN, Buttgereit F. Human Early Fracture hematoma is characterized by inflammation and hypoxia. Clin Orthop Relat Res 2011; 469: 3118-3126.
22. Hoff P, Gaber T, Schmidt-Bleek K, Senturk U, Tran CL, Blankenstein K et al. Immunologically restricted patients exhibit a pronounced inflammation and inadequate response to hypoxia in fracture hematomas. Immunol Res 2011; 51: 116-122.
23. Cornell CN, Lane JM. Newest factors in fracture healing. Clin Orthop Relat Res 1992; 277: 297-311.
24. Hauser CJ, Zhou X, Joshi P, Cuchens MA, Kregor P, Devidas M et al. The immune microenvironment of human fracture/soft-tissue hematomas and its relationship to systemic immunity. J Trauma 1997; 42: 895-903.
25. Gaber T, Dziurla R, Tripmacher R, Burmester GR, Buttgereit F. Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do! Ann Rheum Dis 2005; 64: 971-980.
26. Schipani E, Maes C, Carmeliet G, Semenza GL. Regulation of osteogenesis-angiogenesis coupling by HIFs and VEGF. J Bone Miner Res 2009; 24: 1347-1353.
27. Behr B, Tang C, Germann G, Longaker MT, Quarto N. Locally applied vascular endothelial growth factor a increases the osteogenic healing capacity of human adipose-derived stem cells by promoting osteogenic and endothelial differentiation. Stem Cells 2011; 29: 286-296.
28. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 2009; 284: 6038-6042.
29. Rosenkilde MM, Schwartz TW. The chemokine system-a major regulator of angiogenesis in health and disease. APMIS 2004; 112: 481-495.
30. Bastian O, Pillay J, Alblas J, Leenen L, Koenderman L, Blokhuis T. Systemic inflammation and fracture healing. J Leukoc Biol 2011; 89: 669-673.
31. Yadav A, Saini V, Arora S. MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta 2010; 411: 1570-1579.
32. Street J, Winter D, Wang JH, Wakai A, McGuinness A, Redmond HP. Is human fracture hematoma inherently angiogenic? Clin Orthop Relat Res 2000; 378: 224-237.
33. Arnold R, Brenner D, Becker M, Frey CR, Krammer PH. How T lymphocytes switch between life and death. Eur J Immunol 2006; 36: 1654-1658.